Skip to main content
Autobound logo

Johnson & Johnson news in 2026: 30 dated events

The latest Johnson & Johnson event on this page is dated Sep 28, 2026. globenewswire.com reported: A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple...

Public (JNJ)Pharmaceutical Manufacturing10,000+ employeesjnj.comLinkedIn

Dated events
30
Last 90 days
30
Latest
Sep 28, 2026

News · latest 10

Latest Johnson & Johnson news

  1. Launch
    A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple...Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study for TECVAYLI® (teclistamab) combined with daratumumab, showing durable disease control and prolonged survival in patients with relapsed or refractory multiple myeloma.
    globenewswire.com
  2. In development
    Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic...Johnson & Johnson announced its drug TREMFYA® (guselkumab) met primary and major secondary endpoints in its Phase 4 STAR study for treating adults with active psoriatic arthritis and axial involvement.
    prnewswire.com
  3. In development
    New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term...Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study for its combination therapy of TECVAYLI® and DARZALEX FASPRO® for relapsed or refractory multiple myeloma, showing sustained disease control and survival.
    prnewswire.com
  4. Launch
    European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptideJohnson & Johnson has received approval from the European Commission for its new oral peptide drug, ICOTYDE™ (icotrokinra), for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents.
    globenewswire.com
  5. In development
    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future GrowthJohnson & Johnson's emerging therapy, ICOTYDE (icotrokinra), is expected to significantly reshape the Psoriatic Arthritis (PsA) market.
    globenewswire.com
  6. Spin-off
    Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal$20B · With DePuy Synthes
    theglobeandmail.com
  7. Layoff
    Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal87 roles (reported)
    ad-hoc-news.de
  8. Investment
    Tempo Therapeutics Raises $14.5 Million To Advance Regenerative Tissue Technology Toward CommercializationJohnson & Johnson, through its innovation arm JJDC, participated in a $14.5 million financing round for Tempo Therapeutics.
    pulse2.com
  9. In development
    CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapyJohnson & Johnson's drug TECVAYLI® (teclistamab) received a recommendation for approval from the European Medicines Agency's CHMP for an extended indication to treat adult patients with relapsed/refractory multiple myeloma who have had at least one prior therapy.
    globenewswire.com
  10. Earnings
    Johnson & Johnson stock gains as guidance points to 2026 revenue above USD 100 billionJohnson & Johnson reported adjusted EPS of USD 2.90 on revenue of USD 25.31 billion in its most recent quarter.
    ad-hoc-news.de

Showing 10 of 30 dated events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Johnson & Johnson with the Signal API

One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson news signals (news), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","signal_types":["news"],"limit":20}'

Same industry

News at related companies

Questions about Johnson & Johnson news

What is the latest news on Johnson & Johnson?
The newest event on this page is dated Sep 28, 2026. globenewswire.com reported: A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple.... This page lists 30 dated events for Johnson & Johnson, each with a source link.
What is going on with Johnson & Johnson?
The 10 latest events on this page cover launch (2), in development (4), spin-off (1), layoff (1), investment (1) and earnings (1). The newest: Sep 28, 2026: A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple... (globenewswire.com).
Is Johnson & Johnson laying off employees?
1 layoff event was reported for Johnson & Johnson. The latest: Sep 21, 2026: Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal (ad-hoc-news.de). See the Johnson & Johnson layoffs page for the dated list.

Source. News articles about the company, one source link per event.

Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.

Data as of .

How this data is built →Get it from the Signal API →